Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,689
  • Shares Outstanding, K 12,886
  • Annual Sales, $ 230 K
  • Annual Income, $ -6,660 K
  • 60-Month Beta 0.99
  • Price/Sales 175.61
  • Price/Cash Flow N/A
  • Price/Book 6.40
Trade LEXX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +64.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.15 +46.05%
on 04/25/24
4.00 -21.50%
on 05/10/24
+0.83 (+35.93%)
since 04/16/24
3-Month
1.85 +69.73%
on 04/16/24
6.85 -54.16%
on 03/11/24
+1.00 (+46.73%)
since 02/16/24
52-Week
0.65 +383.97%
on 06/15/23
6.85 -54.16%
on 03/11/24
+2.40 (+324.32%)
since 05/16/23

Most Recent Stories

More News
Lexaria (NASDAQ: LEXX) Partners with National Research Council of Canada for DehydraTECH-GLP-1 Investigation

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced a partnership with the National Research Council of Canada (“NRC”) that will pursue an applied research...

LEXX : 3.14 (+1.95%)
Lexaria (NASDAQ: LEXX) Set to Extend Runway to 2025 Following Warrant Exercise, Issuance

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain...

LEXX : 3.14 (+1.95%)
Lexaria Bioscience (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine...

LEXX : 3.14 (+1.95%)
Lexaria (NASDAQ: LEXX) Targeting Massive Type 2 Diabetes and Obesity Markets with DehydraTECH(TM)

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its...

LEXX : 3.14 (+1.95%)
Lexaria (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed...

LEXX : 3.14 (+1.95%)
Lexaria Bioscience (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing...

LEXX : 3.14 (+1.95%)
Lexaria Bioscience (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board. The potential...

LEXX : 3.14 (+1.95%)
Lexaria (NASDAQ: LEXX) Grows Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally...

LEXX : 3.14 (+1.95%)
Lexaria Bioscience (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will...

LEXX : 3.14 (+1.95%)
Lexaria Bioscience (NASDAQ: LEXX) Focusing on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM)...

LEXXW : 1.3500 (unch)
LEXX : 3.14 (+1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 3.34
2nd Resistance Point 3.27
1st Resistance Point 3.20
Last Price 3.14
1st Support Level 3.06
2nd Support Level 2.99
3rd Support Level 2.92

See More

52-Week High 6.85
Fibonacci 61.8% 4.48
Fibonacci 50% 3.75
Last Price 3.14
Fibonacci 38.2% 3.02
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar